VEGFA and age-related macular degeneration: Currently, anti-VEGF therapy is the most promising treatment in ophthalmology [112], and, because VEGF is produced and acts only locally, the application of nano-encapsulated HN analogues could provide a valuable drug candidate to reduce the pathogenesis characteristic of AMD with minimum toxic effects to cells.